PMC:7195088 / 73087-74320 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"2061","span":{"begin":874,"end":887},"obj":"Species"},{"id":"2062","span":{"begin":893,"end":901},"obj":"Species"},{"id":"2063","span":{"begin":1052,"end":1060},"obj":"Species"},{"id":"2064","span":{"begin":1224,"end":1232},"obj":"Species"},{"id":"2065","span":{"begin":817,"end":824},"obj":"Chemical"},{"id":"2066","span":{"begin":1204,"end":1211},"obj":"Chemical"},{"id":"2067","span":{"begin":1215,"end":1223},"obj":"Disease"}],"attributes":[{"id":"A2061","pred":"tao:has_database_id","subj":"2061","obj":"Tax:11118"},{"id":"A2062","pred":"tao:has_database_id","subj":"2062","obj":"Tax:9606"},{"id":"A2063","pred":"tao:has_database_id","subj":"2063","obj":"Tax:9606"},{"id":"A2064","pred":"tao:has_database_id","subj":"2064","obj":"Tax:9606"},{"id":"A2065","pred":"tao:has_database_id","subj":"2065","obj":"MESH:C558899"},{"id":"A2066","pred":"tao:has_database_id","subj":"2066","obj":"MESH:C558899"},{"id":"A2067","pred":"tao:has_database_id","subj":"2067","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Against this background, the role of the attending physician is crucial, by favouring and not discouraging RCT participation (in favour of off-label administration) whenever the former is possible. Otherwise, scientific data will still be produced, but most information will be burdened by only partially adjustable selection biases and confounding factors, with consequent risks of inconclusive results and low-level supporting evidence for the various treatment options. If participation in RCT is maximized, high-level evidence will be available for guiding treatment, with lower-level evidence from off-label uses still remaining useful for hypothesis-generating purposes in order to better design further RCT (and not for directly guiding treatment choices). Notably, this is what, in our opinion, happened with LPV/RTV: (a) preclinical data supported activity against coronaviruses; (b) patients were enrolled onto RCT whenever possible, and otherwise they were offered off-label administration when not spontaneously improving; (c) because many patients were rapidly enrolled onto the first RCT, evidence rapidly become available that in our opinion discouraged a universal off-label provision of LPV/RTV in COVID-19 patients."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T397","span":{"begin":1215,"end":1223},"obj":"Disease"}],"attributes":[{"id":"A397","pred":"mondo_id","subj":"T397","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"Against this background, the role of the attending physician is crucial, by favouring and not discouraging RCT participation (in favour of off-label administration) whenever the former is possible. Otherwise, scientific data will still be produced, but most information will be burdened by only partially adjustable selection biases and confounding factors, with consequent risks of inconclusive results and low-level supporting evidence for the various treatment options. If participation in RCT is maximized, high-level evidence will be available for guiding treatment, with lower-level evidence from off-label uses still remaining useful for hypothesis-generating purposes in order to better design further RCT (and not for directly guiding treatment choices). Notably, this is what, in our opinion, happened with LPV/RTV: (a) preclinical data supported activity against coronaviruses; (b) patients were enrolled onto RCT whenever possible, and otherwise they were offered off-label administration when not spontaneously improving; (c) because many patients were rapidly enrolled onto the first RCT, evidence rapidly become available that in our opinion discouraged a universal off-label provision of LPV/RTV in COVID-19 patients."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T388","span":{"begin":143,"end":148},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T389","span":{"begin":607,"end":612},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T390","span":{"begin":827,"end":828},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T391","span":{"begin":857,"end":865},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"},{"id":"T392","span":{"begin":890,"end":891},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T393","span":{"begin":980,"end":985},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"},{"id":"T394","span":{"begin":1169,"end":1170},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T395","span":{"begin":1185,"end":1190},"obj":"http://purl.obolibrary.org/obo/CLO_0007225"}],"text":"Against this background, the role of the attending physician is crucial, by favouring and not discouraging RCT participation (in favour of off-label administration) whenever the former is possible. Otherwise, scientific data will still be produced, but most information will be burdened by only partially adjustable selection biases and confounding factors, with consequent risks of inconclusive results and low-level supporting evidence for the various treatment options. If participation in RCT is maximized, high-level evidence will be available for guiding treatment, with lower-level evidence from off-label uses still remaining useful for hypothesis-generating purposes in order to better design further RCT (and not for directly guiding treatment choices). Notably, this is what, in our opinion, happened with LPV/RTV: (a) preclinical data supported activity against coronaviruses; (b) patients were enrolled onto RCT whenever possible, and otherwise they were offered off-label administration when not spontaneously improving; (c) because many patients were rapidly enrolled onto the first RCT, evidence rapidly become available that in our opinion discouraged a universal off-label provision of LPV/RTV in COVID-19 patients."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T38758","span":{"begin":143,"end":148},"obj":"Chemical"},{"id":"T7632","span":{"begin":607,"end":612},"obj":"Chemical"},{"id":"T22983","span":{"begin":980,"end":985},"obj":"Chemical"},{"id":"T82876","span":{"begin":1185,"end":1190},"obj":"Chemical"}],"attributes":[{"id":"A32182","pred":"chebi_id","subj":"T38758","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A14881","pred":"chebi_id","subj":"T7632","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A73415","pred":"chebi_id","subj":"T22983","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"},{"id":"A59992","pred":"chebi_id","subj":"T82876","obj":"http://purl.obolibrary.org/obo/CHEBI_35209"}],"text":"Against this background, the role of the attending physician is crucial, by favouring and not discouraging RCT participation (in favour of off-label administration) whenever the former is possible. Otherwise, scientific data will still be produced, but most information will be burdened by only partially adjustable selection biases and confounding factors, with consequent risks of inconclusive results and low-level supporting evidence for the various treatment options. If participation in RCT is maximized, high-level evidence will be available for guiding treatment, with lower-level evidence from off-label uses still remaining useful for hypothesis-generating purposes in order to better design further RCT (and not for directly guiding treatment choices). Notably, this is what, in our opinion, happened with LPV/RTV: (a) preclinical data supported activity against coronaviruses; (b) patients were enrolled onto RCT whenever possible, and otherwise they were offered off-label administration when not spontaneously improving; (c) because many patients were rapidly enrolled onto the first RCT, evidence rapidly become available that in our opinion discouraged a universal off-label provision of LPV/RTV in COVID-19 patients."}

{"project":"LitCovid-sentences","denotations":[{"id":"T499","span":{"begin":0,"end":197},"obj":"Sentence"},{"id":"T500","span":{"begin":198,"end":472},"obj":"Sentence"},{"id":"T501","span":{"begin":473,"end":763},"obj":"Sentence"},{"id":"T502","span":{"begin":764,"end":1233},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Against this background, the role of the attending physician is crucial, by favouring and not discouraging RCT participation (in favour of off-label administration) whenever the former is possible. Otherwise, scientific data will still be produced, but most information will be burdened by only partially adjustable selection biases and confounding factors, with consequent risks of inconclusive results and low-level supporting evidence for the various treatment options. If participation in RCT is maximized, high-level evidence will be available for guiding treatment, with lower-level evidence from off-label uses still remaining useful for hypothesis-generating purposes in order to better design further RCT (and not for directly guiding treatment choices). Notably, this is what, in our opinion, happened with LPV/RTV: (a) preclinical data supported activity against coronaviruses; (b) patients were enrolled onto RCT whenever possible, and otherwise they were offered off-label administration when not spontaneously improving; (c) because many patients were rapidly enrolled onto the first RCT, evidence rapidly become available that in our opinion discouraged a universal off-label provision of LPV/RTV in COVID-19 patients."}